EXEL – Exelixis, Inc.

Exelixis, Inc.

EXEL

$70.02

Name : Exelixis, Inc.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $17,085,641,728.00

EPSttm : 3.34

Exelixis, Inc.

$70.02

0.79%

$0.56

EXEL — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

11.57

Margin Of Safety %

Put/Call OI Ratio

1.01

EPS Next Q Diff

0.03

EPS Last/This Y

0.67

EPS This/Next Y

0.52

Price

70.55

Target Price

61.57

Analyst Recom

2.47

Performance Q

40.1

Upside

4.1%

Beta

0.42

Ticker: EXEL

22 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-10-12	EXEL	59.8	1.45	0.53	56100
2026-10-13	EXEL	59.51	1.43	0.07	56372
2026-10-14	EXEL	61.02	1.43	0.87	56439
2026-10-15	EXEL	62.81	1.41	0.30	58441
2026-10-16	EXEL	62.25	1.41	0.26	58937
2026-10-19	EXEL	62.52	1.02	0.06	40283
2026-10-20	EXEL	64.41	1.01	0.03	40469
2026-10-21	EXEL	64.57	0.98	0.13	41349
2026-10-22	EXEL	65.31	0.96	0.09	41802
2026-10-23	EXEL	64.56	0.95	0.17	42415
2026-10-26	EXEL	65.12	0.94	0.02	42542
2026-10-27	EXEL	65.35	0.93	0.24	42890
2026-10-28	EXEL	66.31	0.93	1.81	43013
2026-10-29	EXEL	66.26	0.96	7.70	44283
2026-10-30	EXEL	69.38	1.09	0.14	47473
2026-11-02	EXEL	70.09	1.09	0.22	47687
2026-11-03	EXEL	72.32	1.08	0.01	48139
2026-11-04	EXEL	72.78	1.03	0.46	49108
2026-11-05	EXEL	68.65	1.04	0.11	49296
2026-11-06	EXEL	69.54	1.01	0.06	49914
2026-11-09	EXEL	71.9	1.04	0.05	49307
2026-11-10	EXEL	70.56	1.01	0.29	49932
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-10-12	EXEL	59.84	15.2	-	3.59
2026-10-13	EXEL	59.55	15.0	-	3.58
2026-10-14	EXEL	61.04	15.0	-	3.58
2026-10-15	EXEL	62.81	15.0	-	3.58
2026-10-16	EXEL	62.22	15.0	-	3.58
2026-10-19	EXEL	62.63	15.0	-	3.58
2026-10-20	EXEL	62.63	15.0	-	3.58
2026-10-21	EXEL	64.39	15.0	-	3.58
2026-10-22	EXEL	65.30	15.0	-	3.58
2026-10-23	EXEL	64.53	15.0	-	3.58
2026-10-26	EXEL	65.12	15.0	-	3.58
2026-10-27	EXEL	65.36	15.9	-	3.58
2026-10-28	EXEL	66.32	15.9	-	3.58
2026-10-29	EXEL	66.28	15.9	-	3.58
2026-10-30	EXEL	69.38	15.9	-	3.58
2026-11-02	EXEL	70.08	2.1	-	3.69
2026-11-03	EXEL	72.35	6.5	-	3.75
2026-11-04	EXEL	72.77	9.2	-	3.75
2026-11-05	EXEL	68.70	9.2	-	3.75
2026-11-06	EXEL	69.57	9.2	-	3.75
2026-11-09	EXEL	71.73	9.2	-	3.75
2026-11-10	EXEL	70.55	9.2	-	3.75
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-10-12	EXEL	-2.82	-1.25	11.75
2026-10-13	EXEL	-2.82	-1.25	11.75
2026-10-14	EXEL	-2.82	-1.25	11.75
2026-10-15	EXEL	-2.82	-1.25	11.75
2026-10-16	EXEL	-2.79	-1.25	11.75
2026-10-19	EXEL	-2.79	-1.22	11.75
2026-10-20	EXEL	-2.79	-1.22	11.75
2026-10-21	EXEL	-2.79	-1.22	11.75
2026-10-22	EXEL	-2.79	-1.22	11.75
2026-10-23	EXEL	-2.79	-1.22	11.75
2026-10-26	EXEL	-2.79	-1.10	11.75
2026-10-27	EXEL	-2.79	-1.10	11.39
2026-10-28	EXEL	-2.79	-1.10	11.39
2026-10-29	EXEL	-2.79	-1.10	11.39
2026-10-30	EXEL	-2.79	-1.10	11.39
2026-11-02	EXEL	-2.83	-0.69	11.57
2026-11-03	EXEL	-2.83	-0.69	11.57
2026-11-05	EXEL	-2.83	-0.69	11.57
2026-11-06	EXEL	-2.83	-0.69	11.57
2026-11-09	EXEL	-1.76	-0.70	11.57
2026-11-10	EXEL	-1.76	-0.70	11.57
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

0.85

Avg. EPS Est. Current Quarter

1.03

Avg. EPS Est. Next Quarter

0.88

Insider Transactions

-1.76

Institutional Transactions

-0.7

Beta

0.42

Average Sales Estimate Current Quarter

657

Average Sales Estimate Next Quarter

690

Fair Value

70.79

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

4.3

Max Drawdown 5-Year %

-35.4

Target Price

61.57

P/E

21.12

Forward P/E

16.85

PEG

0.87

P/S

6.9

P/B

9.42

P/Free Cash Flow

14.83

EPS

3.34

Average EPS Est. Cur. Y

3.75

EPS Next Y. (Est.)

4.27

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

35.45

Relative Volume

1.51

Return on Equity vs Sector %

Return on Equity vs Industry %

41.7

EPS 1 7Days Diff

0.2

EPS 1 30Days Diff

0.16

EBIT Estimation

◆ EXEL Healthcare

$70.58

📉

Swing / Pullback

Buy the dip on strong trends

WEAK

Trend

20/20

Pullback

8/25

Volume

0/15

Valuation

5/20

TP/AR

4/10

Options

3/10

RSI

65.6

Range 1M

81.4%

Sup Dist

0.8%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

13/25

Growth

18/30

Estimates

10/20

Inst/Vol

7/15

Options

6/10

EPS Yr

20.5%

EPS NY

12.9%

52W%

91.7%

💎

Long-Term Value

Quality companies, undervalued

WATCH

🟡 HOLD +14.1% upside

Quality

28/30

Valuation

8/30

Growth

20/25

Stability

7/10

LT Trend

4/5

Upside

+14.1%

Quality

MoS

EXEL — P/E HistoricalBiotechnology

Exelixis, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 1077

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent oral inhibitor of kinases, including the TAM kinases, MET, and VEGF receptors; XL309, a small molecule inhibitor of USP1, a synthetic lethal target in the context of BRCA-mutated tumors; XB010, an antibody-drug conjugates (ADC) consisting of a MMAE payload conjugated to a monoclonal antibody targeting the tumor antigen 5T4; XB628, a first-in-class bispecific antibody that targets programmed cell death ligand 1and natural killer cell receptor group 2A; and XB371, a next-generation tissue factor targeting ADC with a topoisomerase inhibitor payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Catalent, Inc.; Iconic Therapeutics, Inc.; Adagene Inc.; Invenra, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as business development activities and other collaborations. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

EXEL

Latest News

—

Caricamento notizie per EXEL…

stock quote shares EXEL – Exelixis, Inc. Stock Price stock today

news today EXEL – Exelixis, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch EXEL – Exelixis, Inc. yahoo finance google finance

stock history EXEL – Exelixis, Inc. invest stock market

stock prices EXEL premarket after hours

ticker EXEL fair value insiders trading

EXEL – Exelixis, Inc.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: EXEL

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y